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NONPARAMETRIC ANALYSIS OF COST·
EFFECTIVENESS RATIOS OF PRAVASTATIN IN
PRIMARY PREVENTION OF CARDIOVASCULAR
DISEASE
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OBJECTIVE: To obtain the confidence interval (CI) of
the results of a cost-effectiveness model for the treatment
of hypercholesterolemia.
BACKGROUND: Incremental CE ratios play an impor-
tant role in pharmacoeconomic analysis. However, CI es-
timates for the CE ratio are rare because the underlying
distribution is unknown in most cases. Rather than using
traditional one-way or multiway sensitivity analysis to
explore estimate variability, a nonparametric bootstrap
method is used to generate the CE ratio CI. This is more
robust because it does not make parametric assumptions.
METHODS: 1,000 bootstrap samples were drawn simul-
taneously with replacement from both an empirical distri-
bution and a Monte Carlo experiment. For patient risk
factors we used the complete subs ample of men aged 45-
64 fitting NCEP primary prevention guidelines in the Na-
tional Health and Nutrition Examination Survey III. For
model parameters (e.g., costs, discount rate) values were
randomly drawn from a specified multivariate distribu-
tion. With 1,000 repeated estimates, the 26th and 975th
ranked CE ratios were used to define the 95% confidence
interval. Programming was done in Visual Basic for Ap-
plications (VBA) language. The study perspective was
that of a third party payer. Efficacy and compliance data
were obtained from the WOSCOPS clinical trial. The in-
cremental 5-year cardiovascular health care costs were
derived from a health insurer database.
RESULTS: A 95% CI for the CE ratio resulting from the
nonparametric bootstrap method showed that primary
prevention of cardiovascular disease with pravastatin re-
mained cost-effective.
CONCLUSION: Confidence interval estimation for the
CE ratio is important and will allow individuals to iden-
tify if a new intervention is a good value for cost, while
capturing the inherent imprecision in the underlying CE
model parameter values.
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OBJECTIVE: The purpose of this study was to determine if
differences existed between pharmacological treatments of
peripheral arterial disease (and intermittent claudication)
(PADIIC) with respect to PADIIC-related costs and health
care outcomes in the Department of Defense (DOD) health
care system.
METHODS: A retrospective review of hospital and pre-
scription data was performed to explore the effects of an
exposure to at least 90 days of either aspirin, pentoxifyl-
line, or dypiridamole on various PAD-related outcomes.
The outcomes under study were the number of PAD-
related invasive procedures performed (INV), number of
PAD-related examination procedures performed (EXM),
number of PAD-related hospitalization days incurred
(HDAYS), and the cost of PAD-related procedures per-
formed (COST). The study period encompassed five
years. A covariate representing the pre-study period num-
ber of PAD-related hospitalizations was used to attempt
to control for severity of disease state. General linear
models (GLM) were used in the analyses.
RESULTS: A GLM showed a statistically significant dif-
ference among the treatment groups for a linear combina-
tion of INV, EXM, HDAYS, and COST when controlling
for past PAD-related hospitalizations (p < 0.02). A statis-
tically significant relationship was also found to exist be-
tween treatment groups and INV (p < 0.04). The pentox-
ifylline treatment group was shown to have a statistically
significant higher covariate-adjusted mean INV when
compared to the aspirin treatment group by a post-hoc T
test adjusted for alpha inflation (p = 0.04). Also, PAD-
related past hospitalizations showed a statistically signifi-
cant relationship with a EXM (p < 0.006).
CONCLUSION: The results appear to support the use of
aspirin in PAD as a preventative treatment.
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Smoking is a high-risk behavior that affects the health
and economic welfare of society. Thus, it is important to
quantify the economic burden smoking places on social
institutions in the United States.
OBJECTIVE: The purpose of this review paper is to ana-
lyze smoking cost studies and to provide estimates that
represent the economic costs of smoking from different
perspectives of society, and as a whole.
METHODS: Current Contents (1996-), Health Star
(1970-), and Medline (1966-) databases were searched
through the use of pertinent subject headings and key
words: tobacco use, smoking, cost, and economics. The
internet was utilized to identify potential sources of epi-
demiological and cost information on smoking. Recent
cost-of-illness studies using different methodologies: hu-
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man capital, incidence, and prevalence were chosen for
review based on their relevance.
RESULTS: Preliminary results indicate that the published
cost studies available underestimate the "true" costs of
smoking. The most current articles approximate annual
direct medical costs to health care payers of $50 billion
(1993); inflating to 1997 equals $59 billion or $1,200 per
smoker. Although the latest cost studies do not attempt
to estimate indirect costs, past studies have found indirect
costs to be 1.5-2 times the direct costs. Therefore, using
direct and indirect costs we estimate total smoking costs
to be $150 billion (1993); inflating to 1997 equals $176
billion or $3,500 per smoker.
CONCLUSION: Quantifying the cost of smoking is a
difficult task due to tobacco use infiltrating many aspects
of life and the dependency of cost on perspective. Cost-
of-illness studies provide cost estimation data which can
be useful in aiding decision-makers who are allocating
health care resources.
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Recent lipid therapy clinical trials confirm the treatment
recommendations of the National Cholesterol Education
Program (NCEP) and extend the proven benefits of pri-
mary and secondary prevention to women, elderly, and
high risk patients with average cholesterol.
OBJECTIVE: The purpose of this study was to estimate
and compare the size of the primary and secondary pre-
vention population if lipid treatment recommendations
were based on (1) the NCEP treatment guidelines and the
baseline characteristics of (2) the primary prevention
population in the West of Scotland Coronary Prevention
Study (WOSCOPS) and the Air Force/Texas Coronary
Atherosclerosis Prevention Study (AFCAPS), (3) the sec-
ondary prevention population in the Cholesterol and Re-
current Events (CARE) trial, and the Scandinavian Sim-
vastatin Survival study (4S).
METHODS: Phase 1 data from the third National
Health and Nutrition Examination Survey were used for
analysis.
RESULTS: Following the current NCEP recommenda-
tions, 18.6 and 5.8 million adults would be candidates
for primary prevention and secondary prevention inter-
vention, respectively. If the treatment guidelines were
based on the characteristics of the WOSCOPS or AF-
CAPS patients, the size of the primary prevention popula-
tion would increase by 12.2 million to 30.8 million. Ex-
tending the recommendation based on the characteristics
of the CARE or the 4S study patients would increase the
secondary prevention population size by 2 million to 7.8
55
million.
CONCLUSION: Recent clinical trials suggest that more
than 15% of U.S. adults would benefit from lipid-lower-
ing therapy for primary and secondary prevention of
heart disease. Cost-effectiveness evaluation of lipid-low-
ering strategies should be used as a guide to treatment
decisions.
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The impact of acute renal failure (ARF) on cost was evalu-
ated in elderly patients with congestive heart failure (CHF).
METHODS: We reviewed medical records of 2,176 Con-
necticut Medicare beneficiaries, aged 65 and older who
were hospitalized with CHF, excluding CHF due to se-
vere AS, MS, or primary non-cardiac illness, between
January 1994 and December 1995 at 20 hospitals. ARF
was defined as an increase in serum creatinine level of
25% from admission, to at least 2 mg/dL during hospital-
ization. We excluded patients who did not have at least
two creatinine measurements (N = 251). To avoid in-
cluding patients with ARF as a result of procedures or
complications, we excluded all patients with major com-
plications or procedures during hospitalization (n =
531). Linear regression models were used to examine the
relationship between ARF and length of hospital stay and
hospital cost.
RESULTS: A total of 1,681 patients were included in the
study sample. Of those, 164 (10%) developed ARF dur-
ing hospitalization. After adjusting for confounding ef-
fects of sex, age, history of CHF, history of hypertension,
diabetes, rales, hematocrit, creatinine, systolic blood
pressure, and left ventricular ejection fraction, ARF was
associated with a significant increase in the length of stay
(LOS) by 3.31 days (p < 0.0001) and a significant in-
crease in hospital cost by $2,714 (p < 0.0001).
CONCLUSION: ARF in hospitalized older patients with
CHF is associated with a longer LOS and higher cost.
Strategies to prevent the development of ARF in high-risk
hospitalized patients may provide the opportunity for
marked reductions in cost.
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OBJECTIVE: To calculate the cost of heart failure in Bel-
gium, based on an epidemiological model.
